Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective
Syed Saqib Ali,Ruchika Raj,Tejinder Kaur,Brenna Weadick,Debasis Nayak,Min Ji No,Jane Protos,Hannah Odom,Kajal Anantbhai Desai,Avinash Persaud,Joanne Wang,Raj Govindarajan +11 more
TLDR
Recent developments in nucleoside transporters are reviewed, including their transport characteristics, their role in the regulation of hematopoiesis, and their potential involvement in the occurrence of adverse hematological side effects due to nucleosid drug treatment.Abstract:
Simple Summary Anticancer nucleoside analogs are promising treatments that often result in damaging toxicities and therefore ineffective treatment. Mechanisms of this are not well-researched, but cellular nucleoside transport research in mice might provide additional insight given transport’s role in mammalian hematopoiesis. Cellular nucleoside transport is a notable component of mammalian hematopoiesis due to how mutations within it relate to hematological abnormities. This review encompasses nucleoside transporters, focusing on their inherent properties, hematopoietic role, and their interplay in nucleoside drug treatment side effects. We then propose potential mechanisms to explain nucleoside transport involvement in blood disorders. Finally, we point out and advocate for future research areas that would improve therapeutic outcomes for patients taking nucleoside analog therapies. Abstract Anticancer nucleoside analogs produce adverse, and at times, dose-limiting hematological toxicities that can compromise treatment efficacy, yet the mechanisms of such toxicities are poorly understood. Recently, cellular nucleoside transport has been implicated in normal blood cell formation with studies from nucleoside transporter-deficient mice providing additional insights into the regulation of mammalian hematopoiesis. Furthermore, several idiopathic human genetic disorders have revealed nucleoside transport as an important component of mammalian hematopoiesis because mutations in individual nucleoside transporter genes are linked to various hematological abnormalities, including anemia. Here, we review recent developments in nucleoside transporters, including their transport characteristics, their role in the regulation of hematopoiesis, and their potential involvement in the occurrence of adverse hematological side effects due to nucleoside drug treatment. Furthermore, we discuss the putative mechanisms by which aberrant nucleoside transport may contribute to hematological abnormalities and identify the knowledge gaps where future research may positively impact treatment outcomes for patients undergoing various nucleoside analog therapies.read more
Citations
More filters
Journal ArticleDOI
Platinum-Nucleos(t)ide Compounds as Possible Antimetabolites for Antitumor/Antiviral Therapy: Properties and Perspectives
TL;DR: A short review of the properties and future perspectives of platinum-NAs is presented in this article , where the authors propose these complexes as a new class of antimetabolites and propose new strategies for potentiating anticancer/antiviral activity.
Book ChapterDOI
Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
TL;DR: In this article , the authors discuss potential causes of PDAC chemoresistance and approaches for combating chemoreaction by targeting different pathways and different cellular functions associated with and mediating resistance.
References
More filters
Journal ArticleDOI
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
H. A. Burris,Malcolm J. Moore,J. S. Andersen,M R Green,Mace L. Rothenberg,M R Modiano,M. C. Cripps,Russell K. Portenoy,A M Storniolo,P Tarassoff,R Nelson,F A Dorr,C. D. Stephens,D. D. Von Hoff +13 more
TL;DR: It is demonstrated that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer and confers a modest survival advantage over treatment with5-FU.
Journal ArticleDOI
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
H. von der Maase,S.W. Hansen,J.T. Roberts,Luigi Dogliotti,T. Oliver,M.J. Moore,István Bodrogi,P. Albers,A. Knuth,C.M. Lippert,P. Kerbrat,P. Sanchez Rovira,P. Wersall,S.P. Cleall,D.F. Roychowdhury,I. Tomlin,C.M. Visseren-Grul,Pierfranco Conte +17 more
TL;DR: GC provides a similar survival advantage to MVAC with a better safety profile and tolerability, and this better-risk benefit ratio should change the standard of care for patients with locally advanced and metastatic TCC from MVAC to GC.
Journal ArticleDOI
Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B
Lewis R. Silverman,Erin P. Demakos,Bercedis L. Peterson,Alice B. Kornblith,Jimmie C. Holland,Rosalie Odchimar-Reissig,Richard Stone,Douglas A. Nelson,Bayard L. Powell,Carlos M. DeCastro,John Ellerton,Richard A. Larson,Charles A. Schiffer,James F. Holland +13 more
TL;DR: Aza C treatment results in significantly higher response rates, improved quality of life, reduced risk of leukemic transformation, and improved survival compared with supportive care.
Journal ArticleDOI
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B
Robert J. Mayer,Roger B. Davis,Celia A. Schiffer,Deborah T. Berg,Bayard L. Powell,Philip Schulman,George A. Omura,Joseph O. Moore,O R McIntyre,Frei E rd +9 more
TL;DR: The concept of a dose-response effect for cytarabine in patients with AML who are 60 years of age or younger is supported and the results with the high-dose schedule in this age group are comparable to those reported in similar patients who have undergone allogeneic bone marrow transplantation during a first remission.
Journal ArticleDOI
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
Courtney D. DiNardo,Brian A. Jonas,Vinod Pullarkat,Michael J. Thirman,Jacqueline S. Garcia,Andrew H. Wei,Marina Konopleva,Hartmut Döhner,Anthony Letai,Pierre Fenaux,Elizabeth A. Koller,Violaine Havelange,Brian Leber,Jordi Esteve,Jianxiang Wang,Vlatko Pejša,Roman Hájek,Kimmo Porkka,Árpád Illés,David Lavie,Roberto M. Lemoli,Kazuhito Yamamoto,Sung-Soo Yoon,Jun-Ho Jang,Su-Peng Yeh,Mehmet Turgut,Wan-Jen Hong,Ying Zhou,Jalaja Potluri,Keith W. Pratz +29 more
TL;DR: In previously untreated patients with confirmed AML who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of remission was higher among patients who received azacitidine plus venetoclax than among those who received zsitidine alone.